RT Journal Article
SR Electronic
T1 Advance of Novel Coronavirus Registration Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.16.20034934
DO 10.1101/2020.03.16.20034934
A1 Song, Gao
A1 Cheng, Meng Qun
A1 Wei, Xian Wen
YR 2020
UL http://medrxiv.org/content/early/2020/03/20/2020.03.16.20034934.abstract
AB Background To analyze the characteristics and heterogeneity of clinical trials of Novel Coronavirus(COVID-19) registered in the China Clinical Trial Registry (ChiCTR), and provide data bases and information references for clinical treatmentMethods Statistics of COVID-19 clinical trials registered with ChiCTR as of February 24, 2020 were collected. Descriptive analysis of registration characteristics. The chi-square test is used to compare statistical differences between different study types, intervention methods, study stage, and Primary sponsor.Results 232 COVID-19 studies registered at the ChiCTR were collected. The overall number of COVID-19 registrations was increased. Hubei Province, China has the largest number of registrations. There were significant differences between the number of participants(P=0.000), study duration(P=0.008), study assignment(P=0.000), and blind method(P=0.000) for different study types. Significant differences could be seen in the dimensions of multicenter study(P=0.022), of participants numbe(P=0.000), study duration(P=0.000) and study assignment(P=0.001) for the four intervention methods. There were significant differences in study assignment(P=0.043) between the early and late studies. CMT drugs with high research frequency are chloroquine, lopinavir / ritonavir, and I-IFN; BI was Cell therapy, plasma therapy, Thymosin, and M/P-AB.Conclusions Different study design characteristics have led to significant differences in some aspects of the COVID-19 clinical trial. Timely summary analysis can provide more treatment options and evidence for clinical practice.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialnoneFunding StatementnoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are from China's CHICTR, the data is true. http://www.chictr.org.cn/index.aspx http://www.chictr.org.cn/index.aspx COVID-19Corona virus disease 2019;ChiCTRChina Clinical Trial Registry;PHEICPublic Health Emergency of International Concern;NCPNovel coronavirus pneumonia;ICTRPInternational Clinical Trials Registry Platform;CMTChemical treatment;BIBiologics and immunoregulatory drugs;TCMTraditional Chinese Medicine Treatment;GCPNational Drug Clinical Trial Institutions;I-IFNI-Interferon;PD-1CD279;M/P-ABMonoclonal/Polyclonal Antibodies;vMIPVirus macrophage inflammatory protein;hFABPHeart fatty acid binding protein;G-CSFgranulocyte colony stimulating factor;BPHPbiological preparation of human placenta;FDPGAnti-aging Active Freeze-dried Powder Granules.